BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31358529)

  • 1. Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.
    Shang S; Yang J; Jazaeri AA; Duval AJ; Tufan T; Lopes Fischer N; Benamar M; Guessous F; Lee I; Campbell RM; Ebert PJ; Abbas T; Landen CN; Difeo A; Scacheri PC; Adli M
    Cancer Res; 2019 Sep; 79(18):4599-4611. PubMed ID: 31358529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
    Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
    Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
    Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
    J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.
    Mukherjee A; Huynh V; Gaines K; Reh WA; Vasquez KM
    Cancer Res; 2019 Jul; 79(13):3185-3191. PubMed ID: 31061066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.
    Bharti R; Dey G; Khan D; Myers A; Huffman OG; Saygin C; Braley C; Richards E; Sangwan N; Willard B; Lathia JD; Fox PL; Lin F; Jha BK; Brown JM; Yu JS; Dwidar M; Joehlin-Price A; Vargas R; Michener CM; Longworth MS; Reizes O
    Mol Cancer; 2024 Jun; 23(1):121. PubMed ID: 38853277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
    Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
    Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.
    Song J; Shih IeM; Chan DW; Zhang Z
    Neoplasia; 2009 Jun; 11(6):605-14, 1 p following 614. PubMed ID: 19484149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SREBP2 contributes to cisplatin resistance in ovarian cancer cells.
    Zheng L; Li L; Lu Y; Jiang F; Yang XA
    Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
    Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
    Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
    Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
    Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R; Nardinocchi L; Pistritto G; D'Orazi G
    Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.